Total Payments
$31,207
2024 Payments
$19.99
Companies
6
Transactions
32
Payment Breakdown by Category
Research$18,163 (58.2%)
Other$6,780 (21.7%)
Consulting$4,808 (15.4%)
Travel$942.36 (3.0%)
Food & Beverage$448.76 (1.4%)
Education$64.54 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,163 | 9 | 58.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,780 | 2 | 21.7% |
| Consulting Fee | $4,808 | 2 | 15.4% |
| Travel and Lodging | $942.36 | 5 | 3.0% |
| Food and Beverage | $448.76 | 12 | 1.4% |
| Education | $64.54 | 2 | 0.2% |
Payments by Type
Research
$18,163
9 transactions
General
$13,044
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $17,463 | 8 | $0 (2023) |
| Biogen, Inc. | $11,604 | 5 | $0 (2022) |
| Eisai Inc. | $1,271 | 11 | $0 (2017) |
| Genentech, Inc. | $700.00 | 1 | $0 (2019) |
| Lilly USA, LLC | $104.83 | 5 | $0 (2024) |
| Novo Nordisk Inc | $64.54 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19.99 | 1 | Lilly USA, LLC ($19.99) |
| 2023 | $6,226 | 4 | Eli Lilly and Company ($6,207) |
| 2022 | $11,050 | 5 | Eli Lilly and Company ($7,350) |
| 2021 | $10,766 | 7 | Biogen, Inc. ($6,796) |
| 2020 | $1,130 | 1 | Biogen, Inc. ($1,130) |
| 2019 | $700.00 | 1 | Genentech, Inc. ($700.00) |
| 2017 | $1,315 | 13 | Eisai Inc. ($1,271) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Neuroscience | ||||||
| 06/06/2023 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Neuroscience | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $555.75 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/26/2023 | Eli Lilly and Company | — | — | In-kind items and services | $112.97 | Research |
| Study: ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $5,538.73 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 08/23/2022 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Neuroscience | ||||||
| 08/11/2022 | Eli Lilly and Company | — | — | In-kind items and services | $21.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 02/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $6,314.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 01/20/2022 | Biogen, Inc. | ADUHELM (Biological) | Consulting Fee | Cash or cash equivalent | $3,678.00 | General |
| Category: Neurology | ||||||
| 01/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,015.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 12/09/2021 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,085.00 | General |
| 12/09/2021 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $15.74 | General |
| 08/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $1,707.03 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 06/22/2021 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 06/22/2021 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 05/20/2021 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| 03/03/2021 | Eli Lilly and Company | — | — | In-kind items and services | $2,198.80 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 12/10/2020 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,130.00 | General |
| 10/04/2019 | Genentech, Inc. | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: PRODROMAL TO MILD AD | ||||||
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $448.50 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $279.36 | General |
| 09/12/2017 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $158.27 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $81.00 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $66.75 | General |
| 09/12/2017 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $66.75 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $8,021 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $5,539 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $3,214 | 2 |
| PRODROMAL TO MILD AD | Genentech, Inc. | $700.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $555.75 | 1 |
| ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $112.97 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $21.00 | 1 |
About Michael Mega, MD, PHD
Michael Mega, MD, PHD is a Neurology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437186038.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Mega, MD, PHD has received a total of $31,207 in payments from pharmaceutical and medical device companies, with $19.99 received in 2024. These payments were reported across 32 transactions from 6 companies. The most common payment nature is "" ($18,163).
Ad
Practice Information
- Specialty Neurology
- Location Portland, OR
- Active Since 06/27/2006
- Last Updated 10/20/2016
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1437186038
Products in Payments
- ADUHELM (Biological) $3,678
- AMYVID (Drug) $104.83
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Portland
Kyle Smoot, M.d, M.D
Neurology — Payments: $944,765
Neurology $944,765
Stanley Cohan, M.d, M.D
Neurology — Payments: $664,935
Neurology $664,935
Dr. Chafic Karam, M.d, M.D
Neurology — Payments: $647,064
Neurology $647,064
Dr. John Dolan, D.o, D.O
Neurology — Payments: $550,588
Neurology $550,588
Kiren Kresa-Reahl, M.d, M.D
Neurology — Payments: $421,575
Neurology $421,575
Matthew Brodsky, Md, MD
Neurology — Payments: $244,252
Neurology $244,252